Brig, Switzerland

Petteri Elsner

This inventor holds 1 USPTO granted patent. Top assignee: Noramco Gmbh. Active years: 2020.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Petteri Elsner: Innovator in Continuous Flow Chemistry

Introduction

Petteri Elsner is a notable inventor based in Brig, Switzerland. He has made significant contributions to the field of chemistry, particularly in the area of continuous flow systems. His innovative work has led to advancements in the synthesis of important compounds.

Latest Patents

Petteri Elsner holds a patent for the N-demethylation of morphinan alkaloids. This patent focuses on the N-demethylation of a compound containing a tertiary N-methylamine, specifically targeting morphinan alkaloids. The methodology described in the patent utilizes highly active catalytic palladium (0) in a continuous flow system under elevated temperature and pressure conditions. This process can be applied to the synthesis of noroxymorphone via aerobic palladium-catalyzed continuous flow N-demethylation.

Career Highlights

Elsner is currently associated with Noramco GmbH, where he continues to explore innovative solutions in the field of chemistry. His work has been instrumental in developing efficient methodologies that enhance the synthesis of complex compounds.

Collaborations

Throughout his career, Petteri has collaborated with esteemed colleagues, including Dominique Roberge and Ulrich Weigl. These collaborations have further enriched his research and contributed to the advancement of continuous flow chemistry.

Conclusion

Petteri Elsner's contributions to the field of chemistry, particularly through his patent on N-demethylation processes, highlight his innovative spirit and dedication to advancing scientific knowledge. His work at Noramco GmbH continues to pave the way for future developments in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…